Dr. Martens (DOCS) H1 2025 earnings summary

Executive summary

• First half results met expectations, with revenue and profit declines driven by weak USA boots market and lower wholesale demand, while strategic focus remained on USA DTC turnaround, cost reduction, product-led marketing, and balance sheet strengthening.

• Cost action plan and inventory reduction initiatives implemented, targeting £25m annualized savings by FY26, mainly from headcount reductions.

• Significant reductions in inventory (£69.1m year-over-year) and net debt (£130.2m year-over-year), with successful refinancing completed.

• Interim dividend of 0.85p declared, set at one-third of previous year's total, consistent with prior guidance.

• CEO transition announced, with Ije Nwokorie to take over in the new year.

Financial highlights

• H1 FY25 revenue: £324.6m (down 18% year-over-year, 16% at constant currency); DTC revenue: £183.0m (down 6.8%); Wholesale: £141.6m (down 29%).

• Adjusted EBIT: £(4.3)m (vs. £39.7m profit in H1 FY24); Adjusted PBT: £(17.9)m (vs. £25.2m profit); Reported PBT: £(28.7)m.

• Gross margin: 64.0% (down 0.4pts year-over-year); EBIT margin: -4.7% (down 14.9pts); Adjusted EPS: (1.3)p.

• Exceptional costs of £9.2m–£9.3m, mainly related to cost action program and director joining costs.

• Dividend per share reduced 46% to 0.85p.

Outlook and guidance

• FY25 guidance unchanged: positive USA DTC growth in H2, inventory reduction of ~£40m, net debt target £310m–£330m.

• USA wholesale revenue expected to decline double-digit percentage in FY25; new store openings revised to ~15.

• Capex guidance reduced to ~£30m; exceptional costs expected at ~£15m; blended tax rate c.27%.

• Currency headwind for FY25 estimated at c.£18m to revenue and c.£6m to PBT.

• No price increases planned for Autumn Winter 2025 on like-for-like products.